Compare GIGM & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIGM | NXTC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.3M |
| IPO Year | 2002 | 2019 |
| Metric | GIGM | NXTC |
|---|---|---|
| Price | $1.39 | $4.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 4.3K | ★ 3.3M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $1.55 |
| 52 Week High | $1.89 | $15.74 |
| Indicator | GIGM | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 48.92 |
| Support Level | $1.30 | $4.01 |
| Resistance Level | $1.51 | $10.66 |
| Average True Range (ATR) | 0.04 | 0.89 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 27.03 | 6.28 |
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.